1. OP0088 Immune-related adverse events of cancer immunotherapy – when inflammatory side effects are associated with survival: a single-centre prospective cohort study. (12th June 2018) Authors: Kostine, M.; Mauric, E.; Rouxel, L.; Barnetche, T.; Veillon, R.; Martin, F.; Dutriaux, C.; Dousset, L.; Pham-Ledard, A.; Prey, S.; Beylot-Barry, M.; Daste, A.; Gross-Goupil, M.; Lallier, J.; Ravaud, A.; Forcade, E.; Bannwarth, B.; Truchetet, M.-E.; Richez, C.; Mehsen-Cetre, N. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 94 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. SAT0540 ONE-YEAR OUTCOMES AFTER RHEUMATIC IMMUNE-RELATED ADVERSE EVENTS FROM CHECKPOINT INHIBITORS. (2nd June 2020) Authors: Berard, E.; Barnetche, T.; Rouxel, L.; Dutriaux, C.; Dousset, L.; Prey, S.; Beylot-Barry, M.; Seneschal, J.; Veillon, R.; Vergnenegre, C.; Daste, A.; Domblides, C.; Sionneau, B.; Gross-Goupil, M.; Ravaud, A.; Forcade, E.; Schaeverbeke, T.; Kostine, M. Journal: Annals of the rheumatic diseases Issue: Volume 79(2020)Supplement 1 Page Start: 1227 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗